Kathmere Capital Management LLC Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Kathmere Capital Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 4,123 shares of the company’s stock after purchasing an additional 45 shares during the period. Kathmere Capital Management LLC’s holdings in Eli Lilly and Company were worth $1,934,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Norges Bank purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $3,416,206,000. Moneta Group Investment Advisors LLC increased its position in shares of Eli Lilly and Company by 102,752.2% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after acquiring an additional 5,440,731 shares during the period. Morgan Stanley increased its position in shares of Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after acquiring an additional 3,691,436 shares during the period. Envestnet Asset Management Inc. increased its position in shares of Eli Lilly and Company by 316.9% during the first quarter. Envestnet Asset Management Inc. now owns 2,434,073 shares of the company’s stock worth $217,569,000 after acquiring an additional 1,850,187 shares during the period. Finally, Mizuho Markets Americas LLC grew its stake in Eli Lilly and Company by 2,882.6% during the 1st quarter. Mizuho Markets Americas LLC now owns 1,765,702 shares of the company’s stock worth $18,090,000 after purchasing an additional 1,706,502 shares in the last quarter. Institutional investors and hedge funds own 81.38% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Credit Suisse Group boosted their target price on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $510.00 to $600.00 and gave the company an “overweight” rating in a research report on Wednesday, August 9th. UBS Group increased their price objective on shares of Eli Lilly and Company from $447.00 to $498.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. Barclays boosted their target price on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. Finally, Berenberg Bank lifted their price target on Eli Lilly and Company from $375.00 to $500.00 in a report on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $532.78.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $575.66 on Friday. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The stock has a market capitalization of $546.47 billion, a P/E ratio of 80.06, a P/E/G ratio of 2.47 and a beta of 0.32. Eli Lilly and Company has a 1 year low of $296.32 and a 1 year high of $601.84. The company’s fifty day moving average is $512.56 and its two-hundred day moving average is $438.41.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The business had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. During the same period in the prior year, the business posted $1.25 EPS. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 9.84 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 62.87%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 591 shares of the stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $466.62, for a total value of $275,772.42. Following the completion of the transaction, the insider now directly owns 101,028,219 shares of the company’s stock, valued at $47,141,787,549.78. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, major shareholder Lilly Endowment Inc sold 591 shares of the stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $466.62, for a total value of $275,772.42. Following the sale, the insider now directly owns 101,028,219 shares of the company’s stock, valued at approximately $47,141,787,549.78. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The disclosure for this sale can be found here. Insiders sold 1,010,309 shares of company stock worth $21,095,701,670 over the last 90 days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.